MethylGene Revamps Pipeline As Celgene Backs Off HDAC, Sirtuin Collaboration
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm has high hopes for lifting the clinical hold on MGDC0103.
You may also be interested in...
Day Two At ODAC: Reviewing Drugs To Treat T-Cell Lymphoma In A Difficult Class
FDA appears to have more concerns with Gloucester's HDAC inhibitor Istodax (romidepsin) than with Allos' Folotyn (pralatrexate).
Day Two At ODAC: Reviewing Drugs To Treat T-Cell Lymphoma In A Difficult Class
FDA appears to have more concerns with Gloucester's HDAC inhibitor Istodax (romidepsin) than with Allos' Folotyn (pralatrexate).
Gloucester Pharma Snags $29 Million Series D
As Gloucester Pharma preps for the FDA, the blood-borne cancer developer corrals a D round from Novo and others to gain leverage in partnering talks.